Tenkasi

Oritavancin is an intravenous antibiotic used to treat serious bacterial infections. It belongs to the glycopeptide class and targets gram-positive organisms. This EU-sourced medication is administered in clinical settings for skin and soft tissue infections.

Oritavancin is used to treat certain bacterial infections, including skin and soft tissue infections caused by susceptible gram-positive bacteria. It may be prescribed when other antibiotics are not suitable or effective. The medication works by disrupting bacterial cell wall formation, helping to clear infections.

Patients receiving oritavancin may experience effects such as headache, nausea, or diarrhea. Some individuals report mild injection site reactions like redness or pain. These effects are generally temporary and monitored during administration.

Oritavancin is administered under medical supervision due to its intravenous route. Patients should inform their healthcare provider of any allergies or prior reactions to antibiotics. Monitoring for infusion-related reactions is standard during treatment.

Oritavancin may interact with other medications, particularly those metabolized by liver enzymes. Caution is advised when combining with drugs affecting blood clotting or heart rhythm. Patients should disclose all current medications to their healthcare provider before starting oritavancin.